A Randomized, Double-blind, Multi-center, Three Arm (Pritelivir, Placebo and Zovirax®) Parallel Group, Comparative Trial to Assess the Efficacy and Safety of Pritelivir 5% w/w Ointment for the Treatment of Recurrent Herpes Labialis in Adults - LipP1
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 362
- 主要终点
- Efficacy Measured by Percentage of Subjects With Non-ulcerative Lesions Based on Principal Investigator's Assessment
研究概览
简要总结
Randomized, double-blind, multi-center, three arm parallel group, comparative trial to assess pritelivir ointment safety and efficacy, ie, proportion of subjects with non-ulcerative lesions, in adult subjects with recurrent herpes labialis (RHL) in comparison with placebo or Zovirax® Cream. The start of treatment with trial medication will be initiated by the subject within one hour of noticing the first sign or symptom (eg, prodrome) of a recurrence of herpes labialis. Trial medication will be applied to the affected area 5 times daily for 4 days.
After self-initiation of treatment with trial medication subjects will be assessed daily by the Investigator until complete healing for a maximum of 13 days.
Subjects will document application of trial medication and the status of their lesion in a diary. There will also be blood sampling, ECG measurement and physical examination performed at the investigational site.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Healthy men and women of any ethnic group aged ≥18 years ;
- •Subjects should have experienced ≥4 recurrences of herpes labialis in the previous 12-months period;
- •Subjects should have experienced prodromal symptoms in at least 50% of recurrent Herpes labialis (rHL) episodes and should have developed ulcerative lesions that have progressed through vesicle, ulcer, and crust stages in at least 50% of the episodes;
- •Willingness not to use any topical application (such as cosmetics, lip balm, sunscreens etc...) other than the trial medication in the area of lesion development from start of prodromal symptoms to complete healing;
- •Willingness not to use any systemic and topical anti-Herpes Simplex Virus (HSV) agent during the trial participation including prescription and over-the-counter (OTC) products;
- •Willingness not to use any systemic, anti-inflammatory or analgesic agents from start of prodromal symptoms to healing;
- •Willingness to refrain from mechanical disruption (ie, scrubbing, lancing, shaving) of the prodromal area or lesion after start of treatment with trial medication until end of the trial participation;
- •Women of child bearing potential and males must use adequate contraception;
- •Subject must give written informed consent.
- •Subjects with current lesion may be enrolled, but they must not treat the lesion present at screening/randomization with the trial medication; they should be instructed to wait for their next subsequent lesion
排除标准
- •Known intolerance to pritelivir or any of the ointment ingredients;
- •Known intolerance to Zovirax® Cream or any of the ingredients (ie, acyclovir, cetostearyl alcohol, mineral oil, poloxamer 407, propylene glycol, sodium lauryl sulfate, and white petrolatum) or valacyclovir;
- •Any skin conditions that could interfere with the assessment of herpes labialis recurrences (eg, eczema, psoriasis, acne etc...)
- •Any other condition which in the opinion of the Investigator would interfere with successful completion of this clinical trial
- •Pregnant and/or breastfeeding women
- •Participation in any investigational drug trial within the last 30 days before randomization for this clinical trial
- •Previous treatment with pritelivir tablets
- •Previous participation in a HSV vaccination Trial unless having received placebo.
- •Clinically relevant ECG abnormalities (eg, QTc according to Fridericia: QTcF > 450 ms for males and QTcF > 470 ms for females; PR > 220 ms) at screening.
- •Clinically relevant abnormalities in laboratory indices at screening which in the opinion of the investigator might have an impact on the safety and evaluability of the subject.
- •Known chronic infections which in the opinion of the investigator might have an impact on the safety and evaluability of the subject.
- •Evidence of active malignancy or immunodeficiency disease, or require chronic use of immunosuppressive drugs (eg, systemic steroids) or topical steroids, or chronically use antiviral medication with activity against HSV.
- •HIV positive based on screening labs.
研究组 & 干预措施
Pritelivir 5% w/w ointment
Topical treatment (20 applications), 5 times daily for 4 days
干预措施: Pritelivir 5% w/w ointment (Drug)
Pritelivir ointment matching placebo
Topical treatment (20 applications), 5 times daily for 4 days
干预措施: Pritelivir ointment matching placebo (Drug)
Zovirax® cream
Topical treatment (20 applications), 5 times daily for 4 days
干预措施: Zovirax® cream (Drug)
结局指标
主要结局
Efficacy Measured by Percentage of Subjects With Non-ulcerative Lesions Based on Principal Investigator's Assessment
时间窗: 13 days
The Investigator assessed subjects for lesion stage at every visit as long as lesions were present from Visit 1 to the End of Trial Visit (Day 12± 1) as a maximum. Percentage of subjects with non-ulcerative lesions (i.e, scoring below 3) based on the Principal Investigators Assessment. Lesion stages were defined as follows: 1-Prodrome; 2a-Redness; 2b-Erythema-Redness; 3-Small Blister; 4-Ulcer; 5-Crust; 6-Drying up and healing; 0-Resolved
次要结局
未报告次要终点